September 12, 2005
Functioning Well
MICHAEL WISE, WANG ZHAOHUI and JAMES ZHU
An article on China Daily on intellectual property, written by James Zhu, Zhaohui (Zeo) Wang, and their colleague Michael Wise at Perkins Coie
(article attached: PerkinsCoie_IP_100905.doc)

A comprehensive report on leading Chinese pharmaceutical firms
by BayHelix member Vicky Chen.

"Unleash the Dragon", a feature article about China life science opportunities for Western companies authored by Dr. Zhu Shen, CEO of BioForesight, Inc. was published by "Pharmaceutical Executive", a prominent monthly business trade publication for the pharmaceutical industry. Licensing, outsourcing, partnering, commercialization opportunities and IP protection issues were discussed in the article. The BayHelix Group was formally introduced in a major publication. BayHelix members Kevin Chen, Tony Chen, Yiyou Chen, Ge Li, and Ye Liu were featured in the article.

Western Ways, Good and Bad
Financial Times, July 21, 2004
Mr. Tony Chen, Head of Paul Hastings IP practice in China, writes in the article the battle over a patent for Viagra, which gives a glimpse of several trends in pharmaceutical intellectual property.

CREATING AN EFFICIENT DRUG DEVELOPMENT ENGINE IN ASIA
Jonathan Wang, Ph.D., Managing Director, WI Harper Group, San Francisco; Glenn Rice,Vice President of BioSciences, SRI International
Asia, a "late starter" in biotechnology, is gaining more and more attention from the Western biopharmaceutical companies. There are a number of converging elements which make this emerging markets of great interest to the biopharmaceutical industry. With its low costs, rapidly growing market, favorable governmental support and high quality inexpensive workforces, Asia could become one of the world’s drug development centers. In this report, the authors give an overview of these elements and will discuss how to capture the Asian opportunities.
jwang@wiharper.com

Animal Models of Disease, by Chaoyong Ma, June 2004, Modern Drug Discovery.

Zebrafish – an in vivo model for drug screening, by Chaoyong Ma, 2004, Drug Discovery.

China pharmaceuticals: APIs
UBS Investment Research (May 2004)
By Vicky Chen, MBA
vchen@gsb.uchicago.edu
In China's highly fragmented pharmaceutical industry, we believe newly emerged
API (active pharmaceutical ingredient) manufacturers are positioned for high
growth. The early movers in the sector are equipped with global-standard
manufacturing facilities, complex chemistry skills and currently enjoy relatively
high entry barriers. We initiated coverage of Zhejiang Hisun Pharmaceutical
(Hisun) and Zhejiang Huahai Pharmaceutical (Huahai) on 6 and 7 May 2004.

Productivity Challenge of the Pharmaceutical Industry And Its Implications for Its Researchers (Part II)
BioPharm Quarterly (Mar 2004)
http://www.biopharm.us/htm/Quarterly/March_2004/Productivity.htm
Division of Bio / Pharmaceutical Sciences, Society of Chinese Bioscientists in America (SCBA)
By Steve Yang, Ph.D.
steve_q_yang@groton.pfizer.com

Productivity Challenge of the Pharmaceutical Industry And Its Implications for Its Researchers (Part I)
BioPharm Quarterly (Dec 2003)
http://www.biopharm.us/htm/Quarterly/Dec_2003/Productivity.pdf
Division of Bio / Pharmaceutical Sciences, Society of Chinese Bioscientists in America (SCBA)
By Steve Yang, Ph.D.
steve_q_yang@groton.pfizer.com

Upping the Dosage - Hatch Waxman's Patent Term Extension Should Be Increased
IP Law and Business (August 2003)
By James Zhu, PhD, MBA, JD
jzhu@perkinscoie.com

Maximizing Effective Patent Life of Innovator Drugs
The National Law Journal (July 7, 2003)
By James Zhu, PhD, MBA, JD
jzhu@perkinscoie.com